GLP-1 drugs improve ratio but cut muscle

A systematic review and meta-analysis published in the International Journal of Obesity on 19 June 2026 pooled seven randomised controlled trials (821 participants) and found that GLP-1 receptor agonists at obesity-management doses improve body composition as a proportion of total weight, but still cause a measurable absolute loss of lean mass^[1]. The headline numbers: lean mass as a share of total body weight rose by 1.81 percentage points (95% CI 1.1 to 2.52), while absolute lean mass fell by 1.74 kg on average (95% CI -3.04 to -0.45).

The finding reframes the muscle-loss debate around GLP-1 drugs. The proportional gain means that patients end up with a higher lean-to-fat ratio after treatment, even though they carry less muscle in absolute terms. The authors argue that lean mass loss on its own should not be treated as a reason to avoid these drugs, but they recommend pairing pharmacotherapy with exercise and nutritional support to preserve muscle^[1].

What the meta-analysis measured

The review, led by Ligia Patricia Laverde and colleagues, searched for RCTs comparing GLP-1 receptor agonists at doses approved or studied for obesity (not the lower diabetes-only doses) against placebo. Eligible trials had to report at least one muscle-related outcome: lean mass, skeletal muscle mass, or body composition by DXA or similar direct measurement. Seven trials met the criteria, covering 821 patients with obesity^[1].

The pooled results showed two apparently contradictory outcomes. In relative terms, lean mass as a percentage of total body weight increased by 1.81 percentage points, a statistically significant shift (95% CI 1.1 to 2.52). In absolute terms, patients lost an average of 1.74 kg of lean mass compared with placebo (95% CI -3.04 to -0.45). Both findings are consistent: when total body weight drops substantially (as it does on GLP-1 drugs at obesity doses), the fraction that is lean can rise even if the absolute amount of lean tissue falls^[1].

Semaglutide drove the largest absolute lean mass loss

Subgroup analysis within the meta-analysis found that semaglutide at obesity doses was associated with the largest absolute lean mass reduction: -5.44 kg^[1]. That is considerably more than the pooled average and reflects semaglutide's position as the GLP-1 receptor agonist with the deepest weight-loss effect in completed RCTs at the doses studied. A separate network meta-analysis of 43 RCTs (3,379 participants) published in Diabetes, Obesity and Metabolism in May 2026 confirmed the pattern: liraglutide 1.8 mg, semaglutide 1.0 mg, and tirzepatide 15 mg all significantly decreased lean mass from baseline, with standardised mean differences ranging from -0.50 to -1.09^[2].

Why proportional versus absolute matters

The distinction between proportional and absolute lean mass change is not academic. Clinicians tracking body composition during weight loss care about both. A patient who starts at 120 kg with 35% body fat and ends at 100 kg with 30% body fat has improved their metabolic risk profile even if some of the 20 kg lost was muscle. The proportional improvement signals better overall composition. But the absolute loss matters for functional outcomes: grip strength, fall risk, daily mobility, and long-term sarcopenia risk, especially in older adults.

This meta-analysis does not resolve the functional question because the included trials did not consistently report physical performance measures such as grip strength, gait speed, or muscle quality. That is a gap the authors acknowledge^[1].

What we do not yet know

Several questions remain open. First, the meta-analysis included only seven trials, all against placebo, and the total sample size (821 participants) is modest by weight-management trial standards. Second, the trials varied in duration and in how they measured lean mass (DXA, bioimpedance, or other methods), introducing heterogeneity. Third, none of the included trials systematically tested whether adding resistance exercise or higher protein intake mitigated the lean mass loss. Observational and narrative reviews suggest that exercise helps, but the RCT evidence is thin.

Finally, this analysis covers GLP-1 receptor agonists only. It does not include dual or triple agonists such as tirzepatide (GIP/GLP-1) or retatrutide (GIP/GLP-1/glucagon) at their obesity doses. Whether those agents produce different lean-mass trade-offs at equivalent weight loss is an open question that head-to-head body-composition studies will need to answer.

What this means if you are on a GLP-1 drug

The practical message from this meta-analysis aligns with what clinicians already recommend: GLP-1 receptor agonists are effective for fat loss and improve overall body composition ratios, but they do not spare muscle. If preserving lean mass matters to you, and it should particularly for older adults or anyone at risk of sarcopenia, resistance training and adequate protein intake are the evidence-based countermeasures. The authors explicitly recommend combining pharmacotherapy with nutritional and physical exercise interventions^[1].

For a full overview of semaglutide's clinical profile, see our semaglutide page. If you are taking any GLP-1 receptor agonist and have concerns about muscle health, talk to your prescriber about a plan that includes structured exercise.